Brexpiprazole CAS 913611-97-9 Puritas >99.0% (HPLC) API Factory

Description:

Chemical Name: Brexpiprazole

CAS: 913611-97-9

Puritas: >99.0% (HPLC)

Aspectus: Alba vel Off-White Crystalline pulveris

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Brexpiprazole Intermedia
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl) piperazinum Hydrochloridum CAS 913614-18-3
7-(4-Chlorobutoxy) quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Nomen chemicum	Brexpiprazole
Synonyma	OPC-34712;7-(4-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-unum
CAS Number	913611-97-9
CATTUS Number	RF-PI1982
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C25H27N3O2S
M. Pondus	433.57
Density	1.245±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba vel Off-White Crystalline pulveris
Lepidium sativum	per IR
RT	Sub chirality ut obsequitur
Chloride	Dat reactionem chloride
Aqua	3.0%~4.5%
Liquescens punctum	198.0~202.0℃
Residere in Ignition	<0.20%
Metalla gravis	≤10ppm
Substantiae cognatae
Individual Impurity	<0.50%
Totalis immunditias	<1.00%
EE	>99.0%
Puritas / Analysis Methodus	>99.0% (HPLC, in sicco basis)
Test Standard	Enterprise Standard
Consuetudinem	API

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Brexpiprazole (CAS: 913611-97-9) medicamentum candidatum utile est in curatione et praecavatione perturbationum mentalium, in quibus CNS perturbationes.Brexpiprazole novum medicamentum antipsychoticum est, quod actio- nem serotonin dopamine modulantis inservit et efficaciam adiunctivam tractandi in aegris cum inordinatione depressiva maiore ostendit (MDD).Brexpiprazolus singularem profanum pharmacologicum exhibet, agonista serotonin 5-HT1A et dopamine receptorum 5-HT1A et tanquam plenus adversariorum 5-HT2A et receptorum noradrenalini α1B/2C, cum affinitate subnanomolari ligatura similis.Brexpiprazole ab Otsuka et Lundbeck evoluta est, anno 2015 ab FDA probata est ad curationem schizophreniae et adiunctivam curationem pro tristitia.Brexpiprazole late censetur successor Otsuka medicamento aripiprazoli antipsychotici (nomen artis Abilify) cuius patentes mense Augusto 2014 elapsi sunt.